Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PTSD
Biotech
Neuropsych biotech Engrail closes $157M series B
Engrail CEO Vikram Sudarsan said the new cash extends the company's runway into the middle of 2026.
Max Bayer
Mar 19, 2024 8:00am
JPM's private capital team ‘actively looking’ at psychedelics
Feb 28, 2024 7:00am
Psychedelic biotech MAPS PBC rebrands to Lykos, snags $100M
Jan 5, 2024 10:50am
Psychiatry biotech hopes to Transcend PTSD rivals with new data
Dec 5, 2023 5:45pm
J&J neuroscience drugs take spotlight with lofty revenue goals
Dec 5, 2023 3:38pm
Psychedelics and the next frontier of mental healthcare
Nov 10, 2023 6:00am